These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32281569)

  • 1. [Neoadjuvant chemotherapy for resectable pancreatic cancer].
    Unno M
    Nihon Shokakibyo Gakkai Zasshi; 2020; 117(4):297-301. PubMed ID: 32281569
    [No Abstract]   [Full Text] [Related]  

  • 2. [Postoperative adjuvant chemotherapy for resectable pancreatic cancer].
    Uesaka K
    Nihon Shokakibyo Gakkai Zasshi; 2020; 117(4):308-312. PubMed ID: 32281571
    [No Abstract]   [Full Text] [Related]  

  • 3. Perioperative Therapy for Borderline Resectable Pancreatic Cancer: What and When?
    Kim MP; Katz MHG
    Ann Surg Oncol; 2019 Jun; 26(6):1596-1597. PubMed ID: 30680479
    [No Abstract]   [Full Text] [Related]  

  • 4. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASO Author Reflection: Adjuvant Chemotherapy After Neoadjuvant Chemotherapy in Pancreatic Adenocarcinoma Does Not Lead to Improved Survival in All Patients.
    Olecki EJ; Gusani NJ
    Ann Surg Oncol; 2021 Jun; 28(6):3123. PubMed ID: 33616769
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer.
    Keedy VL; Berlin J
    Curr Treat Options Oncol; 2006 Sep; 7(5):381-8. PubMed ID: 16904055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Future concepts for neoadjuvant and adjuvant treatment of (resectable) pancreatic cancer].
    Seufferlein T; Michalski C
    Chirurg; 2022 May; 93(5):441-445. PubMed ID: 35376964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neoadjuvant therapy vs. upfront resection for resectable pancreatic cancer].
    Strobel O; Büchler MW
    Chirurg; 2017 Jul; 88(7):619. PubMed ID: 28573533
    [No Abstract]   [Full Text] [Related]  

  • 9. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.
    Artinyan A; Anaya DA; McKenzie S; Ellenhorn JD; Kim J
    Cancer; 2011 May; 117(10):2044-9. PubMed ID: 21523715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invited commentary for the article "Evaluation of local recurrence after pancreaticoduodenectomy for borderline resectable pancreatic head cancer with neoadjuvant chemotherapy: Can the resection level change after chemotherapy?".
    Hewitt DB; Wolfgang CL
    Surgery; 2023 May; 173(5):1229-1230. PubMed ID: 36854642
    [No Abstract]   [Full Text] [Related]  

  • 11. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.
    Du L; DeFoe M; Ruzinova MB; Olsen JR; Wang-Gillam A
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):717-26. PubMed ID: 26226906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant and neoadjuvant therapy for pancreatic cancer.
    Vinciguerra V
    Oncology (Williston Park); 2011 Feb; 25(2):192-3. PubMed ID: 21456392
    [No Abstract]   [Full Text] [Related]  

  • 13. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
    Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer.
    Chawla A
    J Surg Oncol; 2021 May; 123(6):1423-1431. PubMed ID: 33831254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist?
    Piątek M; Kuśnierz K; Bieńkowski M; Pęksa R; Kowalczyk M; Nawrocki S
    Crit Rev Oncol Hematol; 2019 Mar; 135():95-102. PubMed ID: 30819452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in the management of borderline resectable pancreatic cancers.
    Goodman MD; McPartland S; Huber K; Saif MW
    JOP; 2013 Jul; 14(4):334-6. PubMed ID: 23846921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hope and frustration of neoadjuvant chemotherapy for resectable pancreatic cancer].
    Lu C; Miao Y; Gao WT
    Zhonghua Wai Ke Za Zhi; 2018 Nov; 56(11):813-816. PubMed ID: 30392300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are we ready for neoadjuvant therapy in potentially resectable pancreatic cancer?
    Philip PA
    Oncology (Williston Park); 2011 Feb; 25(2):189-90, 192. PubMed ID: 21456391
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy.
    Evans DB; George B; Tsai S
    Ann Surg Oncol; 2015 Oct; 22(11):3409-13. PubMed ID: 26122369
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.